Ser253
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser253  -  FOXO1A (mouse)

Site Information
sPRRRAAsMDNNSKF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448075

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 51 , 52 ) , immunoprecipitation ( 3 , 35 ) , mass spectrometry ( 9 , 10 , 11 , 17 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 32 , 33 , 34 , 37 , 38 , 39 , 40 , 41 , 43 ) , mutation of modification site ( 3 , 5 , 12 , 14 , 47 , 50 , 51 , 52 , 53 ) , phospho-antibody ( 1 , 2 , 4 , 5 , 6 , 8 , 11 , 12 , 13 , 14 , 15 , 18 , 19 , 31 , 35 , 36 , 42 , 44 , 46 , 47 , 48 , 49 ) , phosphopeptide mapping ( 11 , 52 ) , western blotting ( 1 , 2 , 4 , 5 , 6 , 7 , 8 , 11 , 12 , 13 , 14 , 15 , 18 , 19 , 31 , 35 , 36 , 42 , 44 , 46 , 47 , 48 , 49 , 53 )
Disease tissue studied:
brain cancer ( 36 ) , glioblastoma ( 36 ) , glioma ( 36 ) , colorectal cancer ( 15 ) , colorectal carcinoma ( 15 ) , liver cancer ( 12 , 14 , 47 , 50 ) , lung cancer ( 15 ) , non-small cell lung cancer ( 15 ) , pancreatic cancer ( 15 ) , pancreatic carcinoma ( 15 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 9 ) , 'brain, embryonic' ( 43 ) , 'brain, embryonic' [BAG1 (mouse)] ( 45 ) , 'muscle, skeletal' ( 42 ) , 'stem, embryonic' ( 42 ) , 293 (epithelial) ( 47 ) , 3T3 (fibroblast) [INSR (mouse), transfection] ( 35 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 48 ) , 3T3 (fibroblast) ( 35 , 46 ) , 3T3-L1 (fibroblast) ( 18 , 37 , 38 , 39 , 40 , 41 ) , A431 (epithelial) ( 15 ) , A549 (pulmonary) ( 15 ) , adipocyte-adipose tissue ( 6 ) , adipose tissue ( 42 ) , BaF3 ('B lymphocyte, precursor') ( 35 ) , C2C12 (myoblast) ( 32 , 33 , 34 ) , COS (fibroblast) ( 35 ) , CV1 (fibroblast) ( 52 ) , DLD1 (intestinal) ( 15 ) , E.coli (bacterial) ( 3 ) , Fao (hepatic) ( 12 , 14 ) , fibroblast-embryo [BAG1 (mouse)] ( 45 ) , fibroblast-lung ( 17 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ) , H4IIe (hepatic) ( 47 , 50 ) , HCT15 (intestinal) ( 15 ) , heart ( 42 ) , HeLa (cervical) ( 15 ) , hepatocyte ( 5 , 51 ) , hepatocyte-liver ( 8 , 11 , 14 , 31 ) , liver ( 2 , 5 , 10 , 11 , 14 , 19 , 20 , 31 , 42 , 44 ) , liver [leptin (mouse), homozygous knockout] ( 10 ) , lymphocyte-spleen ( 4 ) , MEF (fibroblast) ( 36 ) , MEF (fibroblast) [BAG4 (mouse), homozygous knockout] ( 13 ) , MIA PaCa-2 (pancreatic) ( 15 ) , myocyte-heart ( 49 ) , NCI-H1299 (pulmonary) ( 15 ) , PaTu (pancreatic) ( 15 ) , SV40 ( 53 ) , T lymphocyte-spleen ( 1 ) , U-251 MG (glial) ( 36 )

Upstream Regulation
Regulatory protein:
Akt1 (mouse) ( 36 ) , Akt2 (mouse) ( 36 ) , BAG1 (mouse) ( 45 ) , BAG4 (mouse) ( 13 ) , CTLA-4 (mouse) ( 1 ) , DICER1 (mouse) ( 4 ) , GRB10 (human) ( 6 ) , LIMS1 (human) ( 15 ) , LIMS1 (mouse) ( 15 ) , LPIN1 (mouse) ( 31 ) , PDK1 (mouse) ( 42 ) , TORC2 (mouse) ( 5 , 31 ) , VEGF (human) ( 7 )
Putative in vivo kinases:
Akt1 (mouse) ( 49 )
Kinases, in vitro:
Akt1 (mouse) ( 52 )
Putative upstream phosphatases:
DUSP6 (human) ( 12 , 14 )
Phosphatases, in vitro:
DUSP6 (mouse) ( 14 )
Treatments:
4-HT ( 35 ) , anti-CD3/CD28 ( 1 , 4 ) , EGF ( 13 ) , fasting ( 19 ) , H2O2 ( 36 , 46 ) , hepatitis C virus expression ( 2 ) , IGF-1 ( 48 , 51 ) , IGFBP-4 ( 48 ) , IL-3 ( 35 ) , insulin ( 6 , 8 , 9 , 12 , 14 , 18 , 31 , 42 , 47 , 51 , 53 ) , L803-mts ( 44 ) , miRNA ( 4 ) , PDGF ( 18 ) , rapamycin ( 35 ) , refeeding ( 19 ) , siRNA ( 14 ) , TGF-beta ( 4 ) , U0126 ( 46 ) , Wnt ( 48 ) , wortmannin ( 52 )

Downstream Regulation
Effects of modification on FOXO1A:
activity, inhibited ( 7 ) , intracellular localization ( 2 , 12 , 49 , 51 , 52 ) , molecular association, regulation ( 3 ) , phosphorylation ( 51 )
Effects of modification on biological processes:
signaling pathway regulation ( 7 ) , transcription, induced ( 2 ) , transcription, inhibited ( 7 , 12 , 14 , 51 )

References 

1

Lingel H, et al. (2017) CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation. Cell Death Differ 24, 1739-1749
28644433   Curated Info

2

Lerat H, et al. (2017) Hepatitis C virus induces a prediabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem 292, 12860-12873
28559285   Curated Info

3

Yalley A, et al. (2016) Loss of Interdependent Binding by the FoxO1 and FoxA1/A2 Forkhead Transcription Factors Culminates in Perturbation of Active Chromatin Marks and Binding of Transcriptional Regulators at Insulin-sensitive Genes. J Biol Chem 291, 8848-61
26929406   Curated Info

4

Singh Y, Garden OA, Lang F, Cobb BS (2015) MicroRNA-15b/16 Enhances the Induction of Regulatory T Cells by Regulating the Expression of Rictor and mTOR. J Immunol 195, 5667-77
26538392   Curated Info

5

Hogan MF, et al. (2015) Hepatic Insulin Resistance Following Chronic Activation of the CREB Coactivator CRTC2. J Biol Chem 290, 25997-6006
26342077   Curated Info

6

Liu M, et al. (2014) Grb10 Promotes Lipolysis and Thermogenesis by Phosphorylation-Dependent Feedback Inhibition of mTORC1. Cell Metab 19, 967-80
24746805   Curated Info

7

Kanthou C, et al. (2014) Tumour cells expressing single VEGF isoforms display distinct growth, survival and migration characteristics. PLoS One 9, e104015
25119572   Curated Info

8

Rector RS, et al. (2013) Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepatology 57, 2213-23
23359250   Curated Info

9

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

10

Grimsrud PA, et al. (2012) A quantitative map of the liver mitochondrial phosphoproteome reveals posttranslational control of ketogenesis. Cell Metab 16, 672-83
23140645   Curated Info

11

Ozcan L, et al. (2012) Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab 15, 739-51
22503562   Curated Info

12

Jiao P, Feng B, Xu H (2012) Mapping MKP-3/FOXO1 Interaction and Evaluating the Effect on Gluconeogenesis. PLoS One 7, e41168
22848439   Curated Info

13

Rahman P, et al. (2011) Silencer of death domains (SODD) inhibits skeletal muscle and kidney enriched inositol 5-phosphatase (SKIP) and regulates phosphoinositide 3-kinase (PI3K)/Akt signaling to the actin cytoskeleton. J Biol Chem 286, 29758-70
21712384   Curated Info

14

Wu Z, et al. (2010) MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J Clin Invest 120, 3901-11
20921625   Curated Info

15

Eke I, et al. (2010) PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J Clin Invest 120, 2516-27
20530873   Curated Info

16

Saavedra A, et al. (2010) PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ 17, 324-35
19745829   Curated Info

17

Guo A (2010) CST Curation Set: 9028; Year: 2010; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

18

Ng Y, et al. (2010) Cluster analysis of insulin action in adipocytes reveals a key role for Akt at the plasma membrane. J Biol Chem 285, 2245-57
19897488   Curated Info

19

Rodgers JT, Haas W, Gygi SP, Puigserver P (2010) Cdc2-like kinase 2 is an insulin-regulated suppressor of hepatic gluconeogenesis. Cell Metab 11, 23-34
20074525   Curated Info

20

Guo A (2009) CST Curation Set: 7820; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

21

Guo A (2009) CST Curation Set: 6840; Year: 2009; Biosample/Treatment: cell line, mouse lung fibroblasts/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

22

Guo A (2009) CST Curation Set: 6754; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

23

Guo A (2009) CST Curation Set: 6755; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

24

Guo A (2009) CST Curation Set: 6756; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

25

Guo A (2009) CST Curation Set: 6753; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS*/T*) (23C8D2) Rabbit mAb Cat#: 10001, PTMScan(R) Phospho-Akt Substrate Motif (RXRXXS*/T*) Immunoaffinity Beads Cat#: 1979
Curated Info

26

Guo A (2009) CST Curation Set: 6378; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

27

Guo A (2009) CST Curation Set: 6375; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

28

Guo A (2009) CST Curation Set: 6376; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

29

Guo A (2009) CST Curation Set: 6374; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

30

Guo A (2009) CST Curation Set: 6377; Year: 2009; Biosample/Treatment: lung, fibroblast/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

31

Ryu D, et al. (2009) TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. Cell Metab 9, 240-51
19254569   Curated Info

32

Guo A (2009) CST Curation Set: 6163; Year: 2009; Biosample/Treatment: cell line, C2C12/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

33

Guo A (2009) CST Curation Set: 6162; Year: 2009; Biosample/Treatment: cell line, C2C12/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

34

Guo A (2009) CST Curation Set: 6160; Year: 2009; Biosample/Treatment: cell line, C2C12/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

35

van Gorp AG, et al. (2009) AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28, 95-106
18836482   Curated Info

36

Nogueira V, et al. (2008) Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14, 458-70
19061837   Curated Info

37

Possemato A (2008) CST Curation Set: 4894; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

38

Possemato A (2008) CST Curation Set: 4896; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

39

Possemato A (2008) CST Curation Set: 4897; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

40

Possemato A (2008) CST Curation Set: 4745; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

41

Possemato A (2008) CST Curation Set: 4747; Year: 2008; Biosample/Treatment: cell line, 3T3-L1/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

42

Bayascas JR, et al. (2008) Mutation of the PDK1 PH domain inhibits protein kinase B/Akt, leading to small size and insulin resistance. Mol Cell Biol 28, 3258-72
18347057   Curated Info

43

Possemato A (2008) CST Curation Set: 3828; Year: 2008; Biosample/Treatment: tissue, brain, embryonic/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

44

Kaidanovich-Beilin O, Eldar-Finkelman H (2006) Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 316, 17-24
16169938   Curated Info

45

Götz R, et al. (2005) Bag1 is essential for differentiation and survival of hematopoietic and neuronal cells. Nat Neurosci 8, 1169-78
16116448   Curated Info

46

Hu Y, et al. (2005) ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. Mol Biol Cell 16, 3705-18
15930121   Curated Info

47

Perrot V, Rechler MM (2003) Characterization of insulin inhibition of transactivation by a C-terminal fragment of the forkhead transcription factor Foxo1 in rat hepatoma cells. J Biol Chem 278, 26111-9
12724332   Curated Info

48

Longo KA, et al. (2002) Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J Biol Chem 277, 38239-44
12154096   Curated Info

49

Camper-Kirby D, et al. (2001) Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res 88, 1020-7
11375271   Curated Info

50

Tomizawa M, et al. (2000) Insulin inhibits the activation of transcription by a C-terminal fragment of the forkhead transcription factor FKHR. A mechanism for insulin inhibition of insulin-like growth factor-binding protein-1 transcription. J Biol Chem 275, 7289-95
10702299   Curated Info

51

Nakae J, Barr V, Accili D (2000) Differential regulation of gene expression by insulin and IGF-1 receptors correlates with phosphorylation of a single amino acid residue in the forkhead transcription factor FKHR. EMBO J 19, 989-96
10698940   Curated Info

52

Biggs WH, et al. (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci U S A 96, 7421-6
10377430   Curated Info

53

Nakae J, Park BC, Accili D (1999) Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 274, 15982-5
10347145   Curated Info